Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...
Wegovy maker Novo Nordisk filed for U.S. FDA approval of CagriSema, a once-weekly shot that combines two compounds to treat ...
Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a higher dose of its ...
As of February 2025, the semaglutide injection (Ozempic, Wegovy) shortage was resolved. As a result, compounded semaglutide ...
Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...
Medicare enrollees will save more than 50% on out-of-pocket costs for 10 common prescription drugs under their insurance ...
Medicare enrollees could save roughly half of what they usually pay for certain drugs next year, according to a study from ...
The diabetes medication semaglutide has recently become a trendy weight loss treatment. But like every drug, there are ...
Stocktwits on MSN
Eli Lilly’s oral obesity drug passes maintenance test after Wegovy, Zepbound — Wall Street flags win for Viking Therapeutics
The company studied Orforglipron for weight maintenance over 52 weeks in patients who were on 72 weeks of popular injectable ...
Doctors and groups representing employers said they’re increasingly hearing about companies cutting weight loss drugs out of ...
A selective androgen receptor modulator combined with a GLP-1 may induce weight loss for older adults with obesity while ...
Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results